Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.

被引：15

作者：

Loriot, Yohann ^{[1
]}

Powles, Thomas ^{[2
]}

Duran, Climent Miguel Angel ^{[3
]}

Sridhar, Srikala S. ^{[4
]}

Bellmunt, Joaquim ^{[5
]}

Petrylak, Daniel Peter ^{[6
]}

Wang Jing ^{[7
]}

Costa, Nuno Matos ^{[8
]}

Laliberte, Robert J. ^{[7
]}

Di Pietro, Alessandra ^{[9
]}

Grivas, Petros ^{[10
]}

Sternberg, Cora N. ^{[11
]}

机构：

[1] Univ Paris Saclay, Gustave Roussy, INSERM, U981, Villejuif, France

[2] Queen Mary Univ London, St Bartholomews Hosp, Barts Canc Inst, Expt Canc Med Ctr, London, England

[3] Inst Valenciano Oncol, Valencia, Spain

[4] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[5] Harvard Med Sch, Dept Med Oncol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA

[6] Yale Canc Ctr, New Haven, CT USA

[7] Pfizer Inc, Cambridge, MA USA

[8] Pfizer, Porto Salvo, Portugal

[9] Pfizer SRL, Milan, Italy

[10] Univ Washington, Dept Med, Div Oncol, Clin Res Div,Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[11] New York Presbyterian Hosp, Weill Cornell Med, Hematol Oncol, New York, NY USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.438

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

438

引用

页数：3